Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $59 | In Stock | |
10 mg | $89 | In Stock | |
25 mg | $189 | In Stock | |
50 mg | $329 | In Stock | |
200 mg | $558 | In Stock | |
500 mg | $897 | In Stock | |
1 mL x 10 mM (in DMSO) | $65 | In Stock |
Description | Ferrostatin-1 (Fer-1) is a potent and selective inhibitor of ferroptosis. Ferrostatin-1 potently inhibits Erastin-induced ferroptosis in HT-1080 cells with an EC50 of 60 nM. Ferrostatin-1 also exhibits antioxidant and antifungal activities. |
In vitro | METHODS: Human bronchial epithelial cells BEAS-2B were co-treated with LPS (10 mg/L) and Ferrostatin-1 (2 μM) for 16 h. The growth inhibition of the cells was detected by CCK-8 method.
RESULTS: Ferrostatin-1 attenuated the LPS-induced cell damage. [1] METHODS: Human fibrosarcoma cells HT-1080 were treated with Ferrostatin-1 (0.5 μM) and Erastin (10 μM) for 4 h, and ROS levels produced by the cells were measured by Flow Cytometry. RESULTS: Ferrostatin-1 inhibited the Erastin-induced accumulation of cytoplasmic and lipid ROS. [2] METHODS: Mouse hippocampal neuronal cells HT-22 were treated with Ferrostatin-1 (3-12 μM) for 16 h, then treated with 5 mM glutamate for 24 h, and then LDH release was measured. RESULTS: The release of LDH was significantly increased by treatment with glutamate, and the release of LDH was inhibited by Ferrostatin-1 treatment. [3] |
In vivo | METHODS: To investigate whether ferroptosis is associated with LPS-induced acute kidney injury (AKI), Ferrostatin-1 (5 mg/kg) was administered intraperitoneally in a single dose to C57BL/6 mice, and infectious AKI was induced by intraperitoneal injection of LPS (10 mg/kg) 30 min later.
RESULTS: Ferrostatin-1 significantly protected mice from renal dysfunction and tubular injury in LPS-induced AKI. [4] METHODS: To investigate whether iron disorders are associated with acute liver disease and its molecular mechanism, Ferrostatin-1 (2.5 μM/kg) was intraperitoneally injected into ICR mice once a day for three days, followed by intraperitoneal injection of TAA (250 mg/kg/day) for three consecutive days, to establish an acute liver injury (ALI) model in mice. RESULTS: Ferrostatin-1 pretreatment significantly reduced TAA-induced changes in plasma ALT, AST and LDH levels, inhibited the expression of TfR1, Fpn and Ft-L proteins, and decreased iron accumulation without affecting the expression of xCT or GPX4 in the liver. Ferrostatin-1 prevents hepatic iron by decreasing death. [5] |
Cell Research | Cell viability was typically assessed in 384-well format by Alamar Blue fluorescence (ex/em 530/590) measured on a Victor3 plate reader. In some experiments, Trypan Blue dye exclusion counting was performed using an automated cell counter. Cell viability under test conditions is reported as a percentage relative to the negative control treatment [1]. |
Alias | Ferrostatin 1, Ferrostatin-1 (Fer-1) |
Molecular Weight | 262.35 |
Formula | C15H22N2O2 |
Cas No. | 347174-05-4 |
Storage | keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | 5% DMSO+95% Saline: 10 mg/mL (38.12 mM, precipitation) ![]() Ethanol: 26.2 mg/mL (100 mM) DMSO: 45 mg/mL (171.53 mM) ![]() | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/5% DMSO+95% Saline
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.